FILTERED RESULTS
FILTERS
Ads Top
DARK MODE
CHART
    Filters
      Symbols
      Sentiment
      Impact
      Search
      FILTERED RESULTS

        

      Upgrade your plan
      ·

      mrk

      ·

      Merck Locks Infinimmune Alliance To Chase Next-Gen Antibody Drugs

      Biotechnology firm Infinimmune Inc. on Tuesday entered a collaboration with Merck & Co Inc. (NYSE:MRK) to develop antibody candidates using its human-first discovery platform.

      The agreement enables Merck to leverage Infinimmune's proprietary technologies to identify therapies targeting multiple undisclosed programs.

      Merck Secures Exclusive Development And Commercial Rights

      Under the terms, Merck will gain exclusive rights to develop and commercialize antibody candidates generated through the collaboration.

      Under the terms of the agreement, Infinimmune will receive an undisclosed upfront payment and is eligible to receive milestone payments associated with the progress of multiple antibody candidates all totaling up to approximately $838 million.

      Platform Combines Human Data And Machine Learning

      Infinimmune will deploy its Anthrobody discovery platform alongside its ...

      Full story available on Benzinga.com


      Source: Benzinga
      .

      Terra Founder Do Kwon Sentenced to 15 Years in Prison for Fraud